20 studies found for:    Ox40
Show Display Options
Rank Status Study
1 Unknown  Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer
Condition: Advanced Cancer.
Interventions: Drug: Cohort 1 anti-OX40;   Drug: Cohort 2 anti-OX40;   Drug: Cohort 3 anti-OX40;   Biological: Tetanus Day 29;   Biological: Tetanus Day 1;   Biological: KLH Day 1;   Biological: KLH Day 29
2 Withdrawn Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Anti-OX40;   Drug: Ipilimumab
3 Completed A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
Condition: Asthma
Interventions: Drug: huMAb OX40L;   Drug: placebo
4 Recruiting Anti-OX40 Antibody in Head and Neck Cancer Patients
Condition: Head and Neck Cancer
Interventions: Drug: Anti-OX40 antibody administration;   Procedure: Surgical Resection
5 Recruiting Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions
Conditions: Metastatic Breast Cancer;   Lung Metastases;   Liver Metastases
Intervention: Biological: MEDI6469
6 Recruiting Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
Conditions: Metastatic Prostate Cancer;   Cancer of the Prostate;   Prostate Cancer
Interventions: Drug: Anti-OX40;   Radiation: Radiation;   Drug: Cyclophosphamide
7 Recruiting Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer
Condition: Colorectal Neoplasms
Intervention: Drug: MEDI6469
8 Terminated OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
Condition: Cancer
Interventions: Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy
9 Withdrawn Study of Immune Responses in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Intervention: Biological: anti-OX40
10 Recruiting Vasculopathy, Inflammation and Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Biological: Blood samples;   Biological: Biopsy
Condition: Neuroblastoma
Interventions: Drug: cyclophosphamide;   Drug: Fludarabine;   Genetic: GINAKIT Cells
12 Unknown  Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU.
Condition: Critical Ill Patients in SICU
Intervention: Drug: Omegaven 10%
13 Not yet recruiting Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults
Condition: Rabies
Intervention: Biological: rabies vaccine
14 Recruiting A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
Conditions: Advanced Solid Tumors;   Aggressive B-cell Lymphomas
Interventions: Biological: MEDI6469/tremelimumab;   Biological: MEDI6469/MEDI4736;   Biological: MEDI6469/rituximab;   Biological: MEDI6469
15 Recruiting A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Condition: Recurrent or Metastatic Solid Tumors
Interventions: Biological: MEDI6383;   Biological: MEDI6383 and MEDI4736
16 Recruiting A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Condition: Advanced Solid Tumors
Intervention: Biological: MEDI0562
17 Active, not recruiting 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
Condition: Neuroblastoma
Interventions: Genetic: iC9-GD2 T Cell Lymphocytes-frozen cells;   Genetic: iC9-GD2 T Cell Lymphocytes-fresh cells;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: pembrolizumab
18 Recruiting A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Conditions: Sarcoma;   Osteosarcoma;   Neuroblastoma;   Melanoma
Interventions: Biological: Anti-GD2-CAR engineered T cells;   Drug: AP1903;   Drug: Cyclophosphamide
19 Recruiting iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma/VEGAS
Condition: Sarcomas
Interventions: Genetic: GD2 T cells;   Biological: VZV vaccine
20 Completed Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy
Condition: Glomerulonephritis, IGA
Intervention: Procedure: gene transcription and cytometry

Indicates status has not been verified in more than two years